Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Jun 23;13(7):1211.
doi: 10.3390/v13071211.

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Daniele Focosi  1 , Marco Tuccori  2 , Andreina Baj  3 , Fabrizio Maggi  3
Affiliations
Editorial

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Daniele Focosi et al. Viruses. .

Abstract

We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.

Keywords: COVID-19; LyCoV016; REGN10987; SARS-CoV-2; convalescent plasma; etesevimab; imdevimab; immune escape; mutations; neutralizing antibody.

PubMed Disclaimer

Conflict of interest statement

We declare we have no conflict of interest related to this manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO COVID-19 Weekly Epidemiological Update 25 February 2021. Special Edition: Proposed Working Definitions of SARS-CoV-2 Variants of Interest and Variants of Concern. [(accessed on 17 June 2021)];2021 Available online: https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-....
    1. Focosi D., Mazzetti P., Pistello M.M. Viral infection neutralization tests: A focus on SARS-CoV-2 with implications for convalescent plasma therapy. Rev. Med. Virol. 2020;31:e2170. - PMC - PubMed
    1. Focosi D., Novazzi F., Genoni A., Dentali F., Dalla Gasperina D., Baj A., Maggi F. Emergence of SARS-CoV-2 Spike Escape Mutation Q493R After Bamlanivimab/Etesevimab Treatment for COVID-19. Res. Sq. 2021 doi: 10.21203/rs.3.rs-524959/v2. - DOI - PMC - PubMed
    1. Chen J., Gao K., Wang R., Wei G.-W. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies. bioRxiv. 2021 doi: 10.1101/2021.04.12.439473. - DOI - PMC - PubMed
    1. Chen X., Chen Z., Azman A.S., Sun R., Lu W., Zheng N., Zhou J., Wu Q., Deng X., Zhao Z., et al. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination. medRxiv. 2021 doi: 10.1101/2021.05.03.21256506. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources